https://orcid.org/0000-0003-0703-4863
References
- FitzGerald GA. Drugs, industry, and academia. Science. 2008;320(5883):1563. doi:10.1126/science.1161006
- Mansfield E. Academic research and industrial innovation. Res Policy. 1991;20(1):1–12. doi:10.1016/0048-7333(91)90080-A
- Takebe T, Imai R, Ono S. The current status of drug discovery and development as originated in United States academia: the influence of industrial and academic collaboration on drug discovery and development. Clin Transl Sci. 2018;11(6):597–606. doi:10.1111/cts.12577
- Kneller R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discov. 2010;9:867–882. doi:10.1038/nrd3251
- Okuyama R, Tsujimoto M. Background and current status of academic drug discovery–analysis from standing points of industry, universities and government. J Jpn Soc Intellect Prod. 2017. Japanese.
- Shunsuke T, Nobuyoshi K, Hiroyuki A, et al. Requirements for the license-out of drug candidates to pharmaceutical companies. Nihon Yakurigaku Zasshi. 2014;143(4):198–202. Japanese. doi:10.1254/fpj.143.198
- Tanaka H, Aono T. Research on the exclusivity of pharmaceutical-related patents filed by national university corporations. Soc Res Pol Innovat Manag. 2008;263. Japanese.
- Ramy A, Mohamed AR, Amr A. Knowledge management in the pharmaceutical industry between academic research and industry regulations. Knowledge Manag Res Pract. 2020;10:1–17. doi:10.1080/14778238.2020.1767517
- Gaynes R. The discovery of Penicillin—new insights after more than 75 years of clinical use. Emerg Infect Dis. 2017;23(5):849–853. doi:10.3201/eid2305.161556
- Kennedy JP, Wayne HW. How to Invent and Protect Your Invention: A Guide to Patents for Scientists and Engineers. New Jersey: John Wiley & Sons; 2012. doi:10.1002/9781118410103.fmatter
- Bostyn S, Nicolas P. Patent= monopoly: a legal fiction; 2013. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2373471. Accessed July 02, 2021.
- Sugimitsu K. Intellectual property as a marketing tool. JIPAJ. 2017;13(3):4–14.
- Eisenberg RS. Patents and the progress of science: exclusive rights and experimental use. Univ Chicago Law Rev. 1989;56(3):1017–1086. doi:10.2307/1599761
- Turner JS. The nonmanufacturing patent owner: toward a theory of efficient infringement. Cal L Rev. 1998;86(1):179–210. doi:10.2307/3481149
- Caves RE, Whinston MD, Hurwirtz AM. Patent expiration, entry, and competition in the US pharmaceutical industry. Brookings Pap Econ Act. 1991;22(1991):1–66.
- Kitch EW. The nature and function of the patent system. J Law Econ. 1977;20(2):265–290. doi:10.1086/466903
- Ordover JA. A patent system for both diffusion and exclusion. J Econ Perspect. 1991;5(1):43–60. doi:10.1257/jep.5.1.43
- United States. Federal trade commission. 2003 to promote innovation: the proper balance of competition and patent law and policy. DIANE Publishing; 2021. Available from: https://www.ftc.gov/sites/default/files/documents/reports/promote-innovation-proper-balance-competition-and-patent-law-and-policy/innovationrpt.pdf. Accessed May 25, 2021.
- Ponchek T. Does the patent system promote scientific innovation-empirical analysis of patent forward citations. Alb LJ Sci Tech. 2015;25(2):289–338.
- Cockburn I, Long G. The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals. Expert Opin Ther Pat. 2015;25(7):739–742. doi:10.1517/13543776.2015.1040762
- Grabowski HG, DiMasi JA, Long G. The roles of patents and research and development incentives in biopharmaceutical innovation. Health Aff (Millwood). 2015;34(2):302–310. doi:10.1377/hlthaff.2014.1047
- Merges RP. Justifying Intellectual Property. Cambridge Massachusetts London, England: Harvard University Press; 2011:284.
- Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
- Sturgis P, Caroline R, Patten S. Middle alternatives revisited: how the neither/nor response acts as a way of saying “I don’t know?”. Sociol Methods Res. 2014;43(1):15–38. doi:10.1177/0049124112452527
- Lowry PB, Gaskin J. Partial least squares (PLS) structural equation modeling (SEM) for building and testing behavioral causal theory: when to choose it and how to use it. IEEE Trans Prof Commun. 2014;57(2):123–146. doi:10.1109/TPC.2014.2312452
- Shimizu H. Free statistical analysis software HAD: an introduction to its functions and a proposal for its use in statistical learning, education, and research practice. J Media Inf Commun. 2016;1:59–73. Japanese.
- Japan Agency for Medical Research and Development. Intellectual property materials for medical researchers; 2021. Available from: https://www.amed.go.jp/chitekizaisan/chizai_kyouzai.html. Accessed June 20, 2021.